Plant expression systems, a budding way to confront chikungunya and Zika in developing countries?.

F1000Research

Volumn 5, Issue , 2016, Pages

  Cardona Ospina, Jaime A ^a   Sepúlveda Arias, Juan C ^a   Mancilla, L ^a   Gutierrez López, Luis G ^a  

^a UNIVERSIDAD TECNOLÓGICA DE PEREIRA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIKUNGUNYA VIRUS VACCINE; POLYSACCHARIDE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE; ZIKA VIRUS VACCINE;

ARBOVIRUS; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; DEVELOPING COUNTRY; HEALTH CARE COST; HEALTH CARE SYSTEM; HERBAL MEDICINE; HUMAN; IMMUNE RESPONSE; MOLECULAR GENETICS; NICOTIANA BENTHAMIANA; NICOTIANA TABACUM; NONHUMAN; NOTE; PLANT EXPRESSION SYSTEM; POLYMERASE CHAIN REACTION; POTATO; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; TRANSGENE; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS ISOLATION; ZIKA FEVER; ZIKA VIRUS;

EID: 85011277394     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.9502.1     Document Type: Note

References (24)

1. Lau OS, Sun SS: Plant seeds as bioreactors for recombinant protein production. Biotechnol Adv. 2009; 27(6): 1015-22
2. Mor TS: Molecular pharming's foot in the FDA's door: Protalix's trailblazing story. Biotechnol Lett. 2015; 37(11): 2147-50
3. Spök A, Twyman RM, Fischer R, et al.: Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants. Trends Biotechnol. 2008; 26(9): 506-17
4. Chen Q, Lai H, Hurtado J, et al.: Agroinfiltration as an Effective and Scalable Strategy of Gene Delivery for Production of Pharmaceutical Proteins. Adv Tech Biol Med. 2013; 1(1): pii: 103
5. Cardona-Ospina JA, Villamil-Gómez WE, Jimenez-Canizales CE, et al.: Estimating the burden of disease and the economic cost attributable to chikungunya, Colombia, 2014. Trans R Soc Trop Med Hyg. 2015; 109(12): 793-802
6. Villamil-Gómez WE, González-Camargo O, Rodriguez-Ayubi J, et al.: Dengue, chikungunya and Zika co-infection in a patient from Colombia. J Infect Public Health. 2016; 9(5): 684-6
7. Poland GA, Whitaker JA, Poland CM, et al.: Vaccinology in the third millennium: scientific and social challenges. Curr Opin Virol. 2016; 17: 116-25
8. Hefferon K: Plant-derived pharmaceuticals for the developing world. Biotechnol J. 2013; 8(10): 1193-202
9. Yao J, Weng Y, Dickey A, et al.: Plants as Factories for Human Pharmaceuticals: Applications and Challenges. Int J Mol Sci. 2015; 16(12): 28549-65
10. Rosales-Mendoza S, Salazar-González JA, Decker EL, et al.: Implications of plant glycans in the development of innovative vaccines. Expert Rev Vaccines. 2016; 15(7): 915-25
11. He J, Peng L, Lai H, et al.: A plant-produced antigen elicits potent immune responses against West Nile virus in mice. Biomed Res Int. 2014; 2014: 952865
12. Pineo CB, Hitzeroth II, Rybicki EP: Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras. Plant Biotechnol J. 2013; 11(8): 964-75
13. Martins KA, Dye JM, Bavari S: Considerations for the development of Zika virus vaccines. Vaccine. 2016; 34(33): 3711-2
14. Salazar-Gonzalez JA, Angulo C, Rosales-Mendoza S: Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. Vaccine. 2015; 33(31): 3650-8
15. Khan M, Dhanwani R, Rao PV, et al.: Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res. 2012; 167(2): 236-46
16. Verma A, Chandele A, Nayak K, et al.: High yield expression and purification of Chikungunya virus E2 recombinant protein and its evaluation for serodiagnosis. J Virol Methods. 2016; 235: 73-9
17. Weber C, Büchner SM, Schnierle BS: A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice. PLoS Negl Trop Dis. 2015; 9(4): e0003684
18. Bao H, Ramanathan AA, Kawalakar O, et al.: Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine. Viral Immunol. 2013; 26(1): 75-83
19. Chattopadhyay A, Wang E, Seymour R, et al.: A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol. 2013; 87(1): 395-402
20. Chang LJ, Dowd KA, Mendoza FH, et al.: Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014; 384(9959): 2046-52
21. Akahata W, Yang ZY, Andersen H, et al.: A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010; 16(3): 334-8
22. Hallengard D, Lum FM, Kummerer BM, et al.: Prime-boost immunization strategies against Chikungunya virus. J Virol. 2014; 88(22): 13333-43
23. Fric J, Bertin-Maghit S, Wang CI, et al.: Use of human monoclonal antibodies to treat Chikungunya virus infection. J Infect Dis. 2013; 207(2): 319-22
24. Goh LY, Hobson-Peters J, Prow NA, et al.: Monoclonal antibodies specific for the capsid protein of chikungunya virus suitable for multiple applications. J Gen Virol. 2015; 96(Pt 3): 507-12